Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy

Authors: Tai Ma, Zhi-jun Wu, Hui Xu, Chang-hao Wu, Jing Xu, Wan-ren Peng, Lu-lu Fan, Guo-ping Sun

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Recently, evidence has emerged that palliative gastrectomy in patients with stage IV gastric cancer may offer some survival benefits. However, the decision whether to perform primary tumor surgery remains challenging for surgeons, and investigations into models that are predictive of prognosis are scarce. Current study aimed to develop and validate prognostic nomograms for patients with metastatic gastric adenocarcinoma treated with palliative gastrectomy.

Methods

The development dataset comprised 1186 patients from the Surveillance, Epidemiology, and End Results Program who were diagnosed with metastatic gastric adenocarcinoma in 2004–2011, while the validation dataset included 407 patients diagnosed in 2012–2015. Variables were incorporated into a Cox proportional hazards model to identify independent risk factors for survival. Both pre- and postoperative nomograms for predicting 1- or 2-year survival probabilities were constructed using the development dataset. The concordance index (c-index) and calibration curves were plotted to determine the accuracy of the nomogram models. Finally, the cut-off value of the calculated total scores based on preoperative nomograms was set and validated by comparing survival with contemporary cases without primary tumor surgery.

Results

Age, tumor size, location, grade, T stage, N stage, metastatic site, scope of gastrectomy, number of examined lymph node(s), chemotherapy and radiotherapy were risk factors of survival and were included as variables in the postoperative nomogram; the c-indices of the development and validation datasets were 0.701 (95% confidence interval [CI]: 0.693–0.710) and 0.699 (95% CI: 0.682–0.716), respectively. The preoperative nomogram incorporated age, tumor size, location, grade, depth of invasion, regional lymph node(s) status, and metastatic site. The c-indices for the internal (bootstrap) and external validation sets were 0.629 (95% CI: 0.620–0.639) and 0.607 (95% CI: 0.588–0.626), respectively. Based on the preoperative nomogram, patients with preoperative total score > 28 showed no survival benefit with gastrectomy compared to no primary tumor surgery.

Conclusions

Our survival nomograms for patients with metastatic gastric adenocarcinoma undergoing palliative gastrectomy can assist surgeons in treatment decision-making and prognostication.
Literature
1.
go back to reference Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.PubMedCrossRef Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.PubMedCrossRef
2.
go back to reference Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.PubMedCrossRef Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.PubMedCrossRef
3.
go back to reference Chang YR, Han DS, Kong SH, Lee HJ, Kim SH, Kim WH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012;19(4):1231–9.PubMedCrossRef Chang YR, Han DS, Kong SH, Lee HJ, Kim SH, Kim WH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012;19(4):1231–9.PubMedCrossRef
4.
go back to reference Zhang JZ, Lu HS, Huang CM, Wu XY, Wang C, Guan GX, et al. Outcome of palliative total gastrectomy for stage IV proximal gastric cancer. Am J Surg. 2011;202(1):91–6.PubMedCrossRef Zhang JZ, Lu HS, Huang CM, Wu XY, Wang C, Guan GX, et al. Outcome of palliative total gastrectomy for stage IV proximal gastric cancer. Am J Surg. 2011;202(1):91–6.PubMedCrossRef
5.
go back to reference Kulig P, Sierzega M, Kowalczyk T, Kolodziejczyk P, Kulig J. Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol. 2012;38(6):490–6.PubMedCrossRef Kulig P, Sierzega M, Kowalczyk T, Kolodziejczyk P, Kulig J. Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol. 2012;38(6):490–6.PubMedCrossRef
6.
go back to reference Yazici O, Ozdemir N, Duran AO, Menekse S, Sendur MA, Karaca H, et al. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO. Future Oncol. 2016;12(3):343–54.PubMedCrossRef Yazici O, Ozdemir N, Duran AO, Menekse S, Sendur MA, Karaca H, et al. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO. Future Oncol. 2016;12(3):343–54.PubMedCrossRef
7.
go back to reference Chiu CF, Yang HR, Yang MD, Jeng LB, Yang TY, et al. Palliative gastrectomy prolongs survival of metastatic gastric Cancer patients with Normal preoperative CEA or CA19-9 values: a retrospective cohort study. Gastroenterol Res Pract. 2016;2016:6846027.PubMedPubMedCentralCrossRef Chiu CF, Yang HR, Yang MD, Jeng LB, Yang TY, et al. Palliative gastrectomy prolongs survival of metastatic gastric Cancer patients with Normal preoperative CEA or CA19-9 values: a retrospective cohort study. Gastroenterol Res Pract. 2016;2016:6846027.PubMedPubMedCentralCrossRef
8.
go back to reference Hsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care. 2017;16(1):19.PubMedPubMedCentralCrossRef Hsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care. 2017;16(1):19.PubMedPubMedCentralCrossRef
9.
go back to reference Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:577.PubMedPubMedCentralCrossRef Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:577.PubMedPubMedCentralCrossRef
10.
go back to reference He X, Lai S, Su T, Liu Y, Ding Y, Quan S, et al. Survival benefits of gastrectomy in gastric cancer patients with stage IV: a population-based study. Oncotarget. 2017;8(63):106577–86.PubMedPubMedCentralCrossRef He X, Lai S, Su T, Liu Y, Ding Y, Quan S, et al. Survival benefits of gastrectomy in gastric cancer patients with stage IV: a population-based study. Oncotarget. 2017;8(63):106577–86.PubMedPubMedCentralCrossRef
11.
go back to reference Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRef Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRef
12.
go back to reference Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European organisation for Reasearch and treatment of Cancer genitourinary group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.PubMedCrossRef Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European organisation for Reasearch and treatment of Cancer genitourinary group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.PubMedCrossRef
13.
go back to reference Graham J, Heng DY. Real-world evidence in metastatic renal cell carcinoma. Tumori. 2018;104(2):76–82.PubMedCrossRef Graham J, Heng DY. Real-world evidence in metastatic renal cell carcinoma. Tumori. 2018;104(2):76–82.PubMedCrossRef
14.
go back to reference Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol. 2013;20(9):2828–34.PubMedCrossRef Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol. 2013;20(9):2828–34.PubMedCrossRef
15.
go back to reference Lane WO, Thomas SM, Blitzblau RC, Plichta JK, Rosenberger LH, Fayanju OM, et al. Surgical resection of the primary tumor in women with De novo stage IV breast Cancer: contemporary practice patterns and survival analysis. Ann Surg. 2019;269(3):537–44.PubMedPubMedCentralCrossRef Lane WO, Thomas SM, Blitzblau RC, Plichta JK, Rosenberger LH, Fayanju OM, et al. Surgical resection of the primary tumor in women with De novo stage IV breast Cancer: contemporary practice patterns and survival analysis. Ann Surg. 2019;269(3):537–44.PubMedPubMedCentralCrossRef
16.
go back to reference Ahmed S, Leis A, Fields A, Chandra-Kanthan S, Haider K, Alvi R, et al. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study. Cancer. 2014;120(5):683–91.CrossRef Ahmed S, Leis A, Fields A, Chandra-Kanthan S, Haider K, Alvi R, et al. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study. Cancer. 2014;120(5):683–91.CrossRef
17.
go back to reference Ahmed S, Fields A, Pahwa P, Chandra-Kanthan S, Zaidi A, Le D, et al. Surgical resection of primary tumor in asymptomatic or minimally symptomatic patients with stage IV colorectal Cancer: a Canadian Province experience. Clin Colorectal Cancer. 2015;14(4):e41–7.CrossRef Ahmed S, Fields A, Pahwa P, Chandra-Kanthan S, Zaidi A, Le D, et al. Surgical resection of primary tumor in asymptomatic or minimally symptomatic patients with stage IV colorectal Cancer: a Canadian Province experience. Clin Colorectal Cancer. 2015;14(4):e41–7.CrossRef
18.
go back to reference Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.PubMedCrossRef Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.PubMedCrossRef
19.
go back to reference Naffouje SA, Salti GI. Extensive lymph node dissection improves survival among American patients with gastric adenocarcinoma treated surgically: analysis of the National Cancer Database. J Gastric Cancer. 2017;17(4):319–30.PubMedPubMedCentralCrossRef Naffouje SA, Salti GI. Extensive lymph node dissection improves survival among American patients with gastric adenocarcinoma treated surgically: analysis of the National Cancer Database. J Gastric Cancer. 2017;17(4):319–30.PubMedPubMedCentralCrossRef
20.
go back to reference Zhuo C, Ying M, Lin R, Wu X, Guan S, Yang C. Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy. Oncotarget. 2017;8(41):71197–205.PubMedPubMedCentralCrossRef Zhuo C, Ying M, Lin R, Wu X, Guan S, Yang C. Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy. Oncotarget. 2017;8(41):71197–205.PubMedPubMedCentralCrossRef
21.
go back to reference Wang M, Ye Y, Yang Q, Li J, Han C, Wang W, et al. Pre-operative lymph node status of gastric cancer evaluated by multidetector computed tomography. Int J Clin Exp Med. 2015;8(10):18213–24.PubMedPubMedCentral Wang M, Ye Y, Yang Q, Li J, Han C, Wang W, et al. Pre-operative lymph node status of gastric cancer evaluated by multidetector computed tomography. Int J Clin Exp Med. 2015;8(10):18213–24.PubMedPubMedCentral
22.
go back to reference Joo I, Lee JM, Kim JH, Shin CI, Han JK, Choi BI. Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer. J Magn Reson Imaging. 2015;41(3):814–21.CrossRef Joo I, Lee JM, Kim JH, Shin CI, Han JK, Choi BI. Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer. J Magn Reson Imaging. 2015;41(3):814–21.CrossRef
23.
go back to reference Pei Q, Wang L, Pan J, Ling T, Lv Y, Zou X. Endoscopic ultrasonography for staging depth of invasion in early gastric cancer: a meta-analysis. J Gastroenterol Hepatol. 2015;30(11):1566–73.PubMedCrossRef Pei Q, Wang L, Pan J, Ling T, Lv Y, Zou X. Endoscopic ultrasonography for staging depth of invasion in early gastric cancer: a meta-analysis. J Gastroenterol Hepatol. 2015;30(11):1566–73.PubMedCrossRef
24.
go back to reference Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015;6(2):CD009944. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015;6(2):CD009944.
Metadata
Title
Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy
Authors
Tai Ma
Zhi-jun Wu
Hui Xu
Chang-hao Wu
Jing Xu
Wan-ren Peng
Lu-lu Fan
Guo-ping Sun
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6075-5

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine